Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | PGK1 | P00558 | 4/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 12/20 | 0.47 |
| ▸ | PDGFRA | P16234 | 12/20 | 0.47 |
| ▸ | NQO2 | P16083 | 1/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | INSR | P06213 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10272929 | 0.77 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2GLAMAPTPDGFRB | |
| SCHEMBL10272593 | 0.77 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2GLAMAPTPDGFRB | |
| SCHEMBL14450852 | 0.77 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2GLAGAAMAPT | |
| SCHEMBL14450851 | 0.77 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2GLAGAAMAPT | |
| SCHEMBL14308605 | 0.77 | PDE10A (0.40) | ALDH1A1SMN1; SMN2MAPTPDGFRBPDGFRA | |
| SCHEMBL14437924 | 0.75 | PDGFRB (0.63) | ALDH1A1SMN1; SMN2GLAGAAMAPT | |
| SCHEMBL1401366 | 0.75 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2GLAGAAMAPT | |
| SCHEMBL7835404 | 0.74 | PDGFRB (0.49) | ALDH1A1SMN1; SMN2GLAGAAMAPT | |
| SCHEMBL23171118 | 0.73 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2GLAGAAMAPT | |
| SCHEMBL23352099 | 0.73 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2GLAGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902373-B2 | asthma; for treating prostaglandin D2 mediated diseases; e.g. 6-(3-fluorophenyl)-N-[1-(1-methyl-1H-tetrazol-5-yl)piperidin-4-yl]nicotinamide | PFIZER INC (US) | 2011-03-08 | — | — | US | disclosed |
| US-20080146569-A1 | Nicotinamide Derivatives | PFIZER INC. | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146569-A1 | Nicotinamide Derivatives | NNT, NAMPT, NADK | ALDH1A1 148/4885SMN1; SMN2 1371/4885GLA 550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.